AstraZeneca Ends Truqap Phase III Trial For Prostate Cancer After Interim Analysis Falls Short

AstraZeneca has decided to discontinue its Phase III CAPItello-280 clinical trial, which was assessing the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic castration-resistant prostate cancer (mCRPC). The trial aimed to compare this combination against docetaxel and ADT with a placebo.

The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) after a pre-specified interim analysis. The committee concluded that the Truqap combination was unlikely to meet the study’s dual primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS). Despite this, the safety profile of Truqap remained consistent with earlier studies. The company will collaborate with trial investigators to ensure proper patient follow-up, and the data collected will contribute to future research.